Literature DB >> 15623625

Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.

Vincent Fradet1, Laurent Lessard, Louis R Bégin, Pierre Karakiewicz, Anne-Marie Mes Masson, Fred Saad.   

Abstract

PURPOSE: Radical prostatectomy (RP) patients with positive surgical margins are at increased risk for recurrence, emphasizing the need for prognostic markers to stratify probable outcome for optimal patient management decisions. We tested the hypothesis that nuclear localization of nuclear factor (NF)-kappaB, a transcription factor involved in the regulation of cell growth, angiogenesis, invasion, and apoptosis, is associated with an increased risk of biochemical recurrence after RP. EXPERIMENTAL
DESIGN: Analyses addressed data from 42 patients (age range, 52-72 years; mean age, 63.7 years) who exhibited positive surgical margins after RP. Immunohistochemical analysis of NF-kappaB (p65) was performed on the positive margin tissue. A nuclear staining cutoff of >5% was considered positive. The relation between nuclear NF-kappaB expression and biochemical recurrence (prostate-specific antigen >0.3 ng/mL and rising) after RP was tested in univariate and multivariate Cox regression models.
RESULTS: Biochemical recurrence was recorded in 23 patients (54.8%; median follow-up, 3.2 years). Univariate Cox regression demonstrated a 4.9-fold (95% confidence interval, 1.5-16.7; P = 0.01) higher rate of recurrence in men with NF-kappaB > 5%. In the multivariate model, after controlling for primary (P = 0.004) and secondary (P = 0.7) Gleason patterns, lymph node (P = 0.06) and seminal vesicle invasion (P = 0.2), and preoperative prostate-specific antigen (P = 0.009), NF-kappaB > 5% was associated with a 6.2-fold higher risk of biochemical recurrence (95% confidence interval, 1.7-23.5; P = 0.007).
CONCLUSIONS: In univariate and multivariate analysis, NF-kappaB nuclear expression was strongly predictive of biochemical recurrence in patients with positive surgical margins after RP. We propose that nuclear NF-kappaB may serve as a useful independent molecular marker for stratifying patients at risk for recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623625     DOI: 10.1158/1078-0432.CCR-04-0764

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Authors:  Jorge Blando; Tricia Moore; Stephen Hursting; Guiyu Jiang; Achinto Saha; Linda Beltran; Jianjun Shen; John Repass; Sara Strom; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-27

2.  Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism.

Authors:  Matthew B Rettig; David Heber; Jiabin An; Navindra P Seeram; Jian Y Rao; Huiren Liu; Tobias Klatte; Arie Belldegrun; Aune Moro; Susanne M Henning; Deqiong Mo; William J Aronson; Allan Pantuck
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells.

Authors:  Thangaiyan Rabi; Sanjeev Shukla; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2008-12       Impact factor: 4.784

4.  Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.

Authors:  Cong Wang; Yuepeng Ke; Shaoyou Liu; Sharon Pan; Ziying Liu; Hui Zhang; Zhichao Fan; Changyi Zhou; Junchen Liu; Fen Wang
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

5.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Authors:  Liying Zhang; Saleh Altuwaijri; Fangming Deng; Lishi Chen; Priti Lal; Umeshkumar K Bhanot; Ruslan Korets; Sven Wenske; Hans G Lilja; Chawnshang Chang; Howard I Scher; William L Gerald
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

7.  Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Authors:  Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

8.  Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma.

Authors:  Daniela Murtas; Franca Piras; Luigi Minerba; Jorge Ugalde; Michela Piga; Cristina Maxia; Maria Teresa Perra; Paola Sirigu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells.

Authors:  Xiangjie Kong; Xiaoqiang Qian; Liujian Duan; Hailong Liu; Yingjian Zhu; Jun Qi
Journal:  DNA Cell Biol       Date:  2016-09-27       Impact factor: 3.311

10.  Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Authors:  A Seaton; P J Maxwell; A Hill; R Gallagher; J Pettigrew; R H Wilson; D J J Waugh
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.